Baricitinib is a JAK1/JAK2 inhibitor which is approved for the treatment of rheumatoid arthritis and under emergency use authorization for COVID19 and has been tested in other autoimmune diseases and for treatment and prevention of GVHD. Here, JAK1 is linked to graft versus host disease.